176 related articles for article (PubMed ID: 29681389)
1. A Microbiota-Dependent, STAT3-Driven Mouse Model of Cutaneous T-Cell Lymphoma.
Wu X; Hwang ST
J Invest Dermatol; 2018 May; 138(5):1022-1026. PubMed ID: 29681389
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
4. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma.
Koh HK; Charif M; Weinstock MA
Hematol Oncol Clin North Am; 1995 Oct; 9(5):943-60. PubMed ID: 8522490
[TBL] [Abstract][Full Text] [Related]
9. Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma.
Fanok MH; Sun A; Fogli LK; Narendran V; Eckstein M; Kannan K; Dolgalev I; Lazaris C; Heguy A; Laird ME; Sundrud MS; Liu C; Kutok J; Lacruz RS; Latkowski JA; Aifantis I; Ødum N; Hymes KB; Goel S; Koralov SB
J Invest Dermatol; 2018 May; 138(5):1116-1125. PubMed ID: 29128259
[TBL] [Abstract][Full Text] [Related]
10. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants.
Slater DN
Br J Dermatol; 2005 Nov; 153(5):874-80. PubMed ID: 16225594
[TBL] [Abstract][Full Text] [Related]
11. Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome.
Shikama N
Chin Clin Oncol; 2019 Feb; 8(1):8. PubMed ID: 30180750
[TBL] [Abstract][Full Text] [Related]
12. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
13. Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter.
Choi MY; Lechowicz MJ
Cancer J; 2012; 18(5):439-44. PubMed ID: 23006949
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage.
Kerschmann RL; Berger TG; Weiss LM; Herndier BG; Abrahms KM; Heon V; Schulze K; Kaplan LD; Resnik SD; LeBoit PE
Arch Dermatol; 1995 Nov; 131(11):1281-8. PubMed ID: 7503572
[TBL] [Abstract][Full Text] [Related]
15. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
16. Memorials and mandates for cutaneous lymphomas.
Heald PW
Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
[No Abstract] [Full Text] [Related]
17. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.
Introcaso CE; Micaily B; Richardson SK; Junkins-Hopkins JM; Yoon JS; Kim EJ; Vittorio CC; Rook AH
J Am Acad Dermatol; 2008 Apr; 58(4):592-5. PubMed ID: 18249469
[TBL] [Abstract][Full Text] [Related]
18. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
19. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas.
Lazaridou I; Ram-Wolff C; Bouaziz JD; Bégon E; Battistella M; Rivet J; Jachiet M; Bagot M; de Masson A
Acta Derm Venereol; 2020 Sep; 100(16):adv00271. PubMed ID: 32556342
[No Abstract] [Full Text] [Related]
[Next] [New Search]
